Analyst picks & changes

Genentech Inc.


Analysts had mixed reactions to


's decision to extend its option to buy the remainder of GNE (see BioCentury Extra May 2).

Jeffrey Casdin of Merrill Lynch reduced his long-term rating from "above average" to "neutral," saying the stock now is almost dead

Read the full 472 word article

How to gain access

Continue reading with a
two-week free trial.